Immunovant will stop IMVT-1402 development in cutaneous lupus after the Phase 1/2 study missed its primary endpoint, despite positive efficacy trends.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
Immunovant has stopped development of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus after its Phase 1/2 proof-of-concept study failed to achieve statistical significance on the primary clinical endpoint at Week 12, despite numerical improvements across several measures and a favorable safety profile.
CLE Study Missed the Primary Endpoint
The randomized, double-blind, placebo-controlled global study (NCT06980805), evaluated IMVT-1402 in 57 adults with cutaneous lupus erythematosus (CLE), an autoimmune disease that primarily affects the skin and can cause persistent inflammatory lesions, scarring, and substantial effects on quality of life.
In Period 1, participants received IMVT-1402 or placebo for 12 weeks. The primary endpoint was the percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12.
The study did not achieve statistical significance on this endpoint. Immunovant reported numerical trends favoring IMVT-1402 across multiple efficacy measures, but the observed clinical activity did not meet the company’s internal threshold for continued development in CLE.
Deeper IgG Reduction Linked to Better Responses
IMVT-1402 is an antibody targeting the neonatal Fc receptor (FcRn), a pathway that regulates the recycling and persistence of immunoglobulin G (IgG) antibodies in circulation. FcRn inhibition increases IgG clearance, reducing circulating pathogenic antibodies that can contribute to autoimmune disease.
The CLE findings provided evidence of a relationship between pharmacodynamic activity and clinical response. Patients who achieved deeper reductions in IgG from baseline were more likely to experience improved clinical outcomes.
However, the relationship did not translate into a statistically significant result on the study’s primary endpoint. Immunovant therefore concluded that the efficacy signal was insufficient to justify continued development in CLE, particularly given the competitive treatment landscape.
Favorable Safety Profile Maintained
IMVT-1402 showed a favorable safety and tolerability profile in the study, consistent with findings from its previous clinical development programs.
The safety findings did not drive the decision to discontinue CLE development. Instead, the decision reflected the overall efficacy results and Immunovant’s assessment of the competitive landscape.
Broader IMVT-1402 Program Continues
The company will discontinue development of IMVT-1402 in CLE but plans to continue advancing the FcRn inhibitor in other autoimmune diseases with significant unmet need.
Current development programs include Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjögren’s disease. Immunovant stated that timelines for these programs remain on track.
Eric Venker, M.D., Pharm.D., Immunovant’s CEO, said the CLE study will contribute to the company’s understanding of FcRn inhibition in autoimmune disease and thanked the patients, investigators, and clinical site teams involved in the trial.
The CLE outcome narrows the clinical scope of IMVT-1402 while leaving its broader autoimmune development strategy unchanged. Future data from the company’s ongoing programs will determine whether the IgG-lowering profile observed with IMVT-1402 translates into clinically meaningful benefits across other FcRn-sensitive diseases.
Reference
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus, Immunovant, 23 September 2026
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE), ClinicalTrials.gov ID NCT06980805
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.